Wolverine Trading’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $6.46M | Buy |
+43,600
| New | +$6.6M | ﹤0.01% | 1208 |
|
|
2025
Q2 | – | Sell |
-66,900
| Closed | -$9.87M | – | 4733 |
|
|
2025
Q1 | $9.87M | Buy |
66,900
+17,050
| +34% | +$2.47M | 0.01% | 648 |
|
|
2024
Q4 | $6.54M | Buy |
49,850
+19,800
| +66% | +$2.77M | 0.01% | 1029 |
|
|
2024
Q3 | $4.66M | Buy |
30,050
+3,700
| +14% | +$597K | ﹤0.01% | 1088 |
|
|
2024
Q2 | $4.11M | Buy |
26,350
+9,000
| +52% | +$1.35M | ﹤0.01% | 1092 |
|
|
2024
Q1 | $2.35M | Sell |
17,350
-3,850
| -18% | -$510K | ﹤0.01% | 1484 |
|
|
2023
Q4 | $2.86M | Sell |
21,200
-103,550
| -83% | -$13.5M | ﹤0.01% | 1442 |
|
|
2023
Q3 | $16.9M | Buy |
124,750
+97,750
| +362% | +$13.4M | 0.02% | 429 |
|
|
2023
Q2 | $3.83M | Sell |
27,000
-25,200
| -48% | -$3.71M | ﹤0.01% | 1056 |
|
|
2023
Q1 | $7.22M | Buy |
52,200
+25,300
| +94% | +$3.4M | 0.01% | 662 |
|
|
2022
Q4 | $3.65M | Buy |
26,900
+800
| +3% | +$100K | 0.01% | 1054 |
|
|
2022
Q3 | $2.87M | Sell |
26,100
-9,150
| -26% | -$1.16M | ﹤0.01% | 1156 |
|
|
2022
Q2 | $4.72M | Sell |
35,250
-1,750
| -5% | -$230K | 0.01% | 832 |
|
|
2022
Q1 | $4.97M | Buy |
+37,000
| New | +$4.44M | 0.01% | 1079 |
|
|
2021
Q4 | – | Sell |
-92,200
| Closed | -$11M | – | 5798 |
|
|
2021
Q3 | $11M | Buy |
+92,200
| New | +$10.7M | 0.01% | 756 |
|
|
2021
Q2 | – | Sell |
-80,000
| Closed | -$8M | – | 5938 |
|
|
2021
Q1 | $8M | Sell |
80,000
-35,300
| -31% | -$3.55M | 0.01% | 824 |
|
|
2020
Q4 | $11.6M | Buy |
115,300
+65,700
| +132% | +$6.96M | 0.02% | 612 |
|
|
2020
Q3 | $5.47M | Sell |
49,600
-11,900
| -19% | -$1.32M | 0.01% | 811 |
|
|
2020
Q2 | $6.51M | Buy |
61,500
+36,800
| +149% | +$3.8M | 0.02% | 674 |
|
|
2020
Q1 | $2.2M | Sell |
24,700
-2,650
| -10% | -$249K | 0.01% | 1270 |
|
|
2019
Q4 | $2.74M | Sell |
27,350
-14,150
| -34% | -$1.33M | 0.01% | 1579 |
|
|
2019
Q3 | $3.76M | Buy |
41,500
+5,450
| +15% | +$473K | 0.01% | 1035 |
|
|
2019
Q2 | $2.98M | Buy |
+36,050
| New | +$2.83M | 0.01% | 1229 |
|
|
2019
Q1 | – | Sell |
-37,650
| Closed | -$2.84M | – | 4501 |
|
|
2018
Q4 | $2.84M | Sell |
37,650
-22,050
| -37% | -$1.72M | 0.01% | 1162 |
|
|
2018
Q3 | $4.72M | Buy |
59,700
+23,900
| +67% | +$1.81M | 0.01% | 1007 |
|
|
2018
Q2 | $2.5M | Hold |
35,800
| – | – | 0.01% | 1391 |
|
|
2018
Q1 | $2.5M | Buy |
+35,800
| New | +$2.48M | 0.01% | 1391 |
|
|
2017
Q4 | – | Sell |
-41,900
| Closed | -$2.84M | – | 4874 |
|
|
2017
Q3 | $2.84M | Sell |
41,900
-44,900
| -52% | -$2.84M | 0.01% | 1109 |
|
|
2017
Q2 | $5.92M | Buy |
86,800
+55,500
| +177% | +$3.62M | 0.03% | 591 |
|
|
2017
Q1 | $1.95M | Buy |
31,300
+2,400
| +8% | +$140K | 0.01% | 1210 |
|
|
2016
Q4 | $1.58M | Sell |
28,900
-20,100
| -41% | -$1.14M | 0.01% | 1520 |
|
|
2016
Q3 | $3.24M | Buy |
+49,000
| New | +$3.2M | 0.02% | 983 |
|
Other funds holding AZN
Wolverine Trading's AZN Position: Q3 2025 in Review
Wolverine Trading opened a new position in AstraZeneca (AZN) in Q3 2025: 8,596 shares worth $1.27M. The stake represents ﹤0.01% of the portfolio and ranks #2644 among its holdings. This is a return to the name: Wolverine Trading previously reported a position in AZN as recently as Q1 2025.
Wolverine Trading first reported a position in AZN in Q4 2016 and has held it in 26 quarters since. The position peaked at $5.47M in Q1 2025. 1,287 funds tracked by Wall St. Rank hold AZN as of Q3 2025.
- Wolverine Trading held 8,596 shares of AstraZeneca worth $1.27M as of Q3 2025.
- AstraZeneca was a new Wolverine Trading position in Q3 2025.
- AstraZeneca made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #2644 holding.
- Wolverine Trading first reported a position in AstraZeneca in Q4 2016 and has held it in 26 quarters since.
- Wolverine Trading's AstraZeneca position peaked at $5.47M in Q1 2025.
- 1,287 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2025.
Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.